Suppr超能文献

评估参与细胞骨架破坏诱导凋亡的神经元凋亡途径。

Evaluation of the neuronal apoptotic pathways involved in cytoskeletal disruption-induced apoptosis.

作者信息

Jordà Elvira G, Verdaguer Ester, Jimenez Andrés, Arriba S Garcia de, Allgaier Clemens, Pallàs Mercè, Camins Antoni

机构信息

Unitat de Farmacologia i Farmacognòsia, Facultat de Farmàcia, Universitat de Barcelona, Nucli Universitari de Pedralbes, E-08028 Barcelona, Spain.

出版信息

Biochem Pharmacol. 2005 Aug 1;70(3):470-80. doi: 10.1016/j.bcp.2005.04.036.

Abstract

The cytoskeleton is critical to neuronal functioning and survival. Cytoskeletal alterations are involved in several neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. We studied the possible pathways involved in colchicine-induced apoptosis in cerebellar granule neurons (CGNs). Although colchicine evoked an increase in caspase-3, caspase-6 and caspase-9 activation, selective caspase inhibitors did not attenuate apoptosis. Inhibitors of other cysteine proteases such as PD150606 (a calpain-specific inhibitor), Z-Phe-Ala fluoromethyl ketone (a cathepsins-inhibitors) and N(alpha)-p-tosyl-l-lysine chloromethyl ketone (serine-proteases inhibitor) also had no effect on cell death/apoptosis induced by colchicine. However, BAPTA-AM 10 microM (intracellular calcium chelator) prevented apoptosis mediated by cytoskeletal alteration. These data indicate that calcium modulates colchicine-induced apoptosis in CGNs. PARP-1 inhibitors did not prevent apoptosis mediated by colchicine. Finally, colchicine-induced apoptosis in CGNs was attenuated by kenpaullone, a cdk5 inhibitor. Kenpaullone and indirubin also prevented cdk5/p25 activation mediated by colchicine. These findings indicate that cytoskeletal alteration can compromise cdk5 activation, regulating p25 formation and suggest that cdk5 inhibitors attenuate apoptosis mediated by cytoskeletal alteration. The present data indicate the potential therapeutic value of drugs that prevent the formation of p25 for the treatment of neurodegenerative disorders.

摘要

细胞骨架对神经元的功能和存活至关重要。细胞骨架改变与多种神经退行性疾病有关,如阿尔茨海默病和帕金森病。我们研究了秋水仙碱诱导小脑颗粒神经元(CGNs)凋亡可能涉及的途径。尽管秋水仙碱可引起半胱天冬酶-3、半胱天冬酶-6和半胱天冬酶-9的激活增加,但选择性半胱天冬酶抑制剂并不能减轻细胞凋亡。其他半胱氨酸蛋白酶抑制剂,如PD150606(一种钙蛋白酶特异性抑制剂)、Z-苯丙氨酸-丙氨酸氟甲基酮(一种组织蛋白酶抑制剂)和N(α)-对甲苯磺酰-L-赖氨酸氯甲基酮(丝氨酸蛋白酶抑制剂)对秋水仙碱诱导的细胞死亡/凋亡也没有影响。然而,10微摩尔的BAPTA-AM(细胞内钙螯合剂)可防止由细胞骨架改变介导的细胞凋亡。这些数据表明,钙可调节秋水仙碱诱导的CGNs细胞凋亡。聚(ADP-核糖)聚合酶-1(PARP-1)抑制剂不能阻止秋水仙碱介导的细胞凋亡。最后,cdk5抑制剂肯帕罗酮可减轻秋水仙碱诱导的CGNs细胞凋亡。肯帕罗酮和靛玉红也可阻止秋水仙碱介导的cdk5/p25激活。这些发现表明细胞骨架改变可损害cdk5激活,调节p25的形成,并提示cdk5抑制剂可减轻由细胞骨架改变介导的细胞凋亡。目前的数据表明,阻止p25形成的药物在治疗神经退行性疾病方面具有潜在的治疗价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验